CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out

Résumé détaillé
CG Oncology said Monday its experimental bladder cancer treatment cut the risk of recurrence by 68%. The biotech stock broke out. The post CG Oncology Exceeds Even The 'Most…
CG Oncology (CGON) said Monday its experimental bladder cancer treatment cut the risk of recurrence by 68%. The news sent the biotech stock flying into breakout territory. "We see these results as meaningfully exceeding both the powering expectations (~30%) and investor expectations (~40%), and even in our most bullish conversations we did not hear investors expect a risk reduction greater…
Début de l'article, extrait de Investor's Business Daily. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.investors.com)